Refractory Escherichia Coli Pneumonia: A Case Report



pulmonary embolism heart failure :: Article Creator

Pulmonary Embolism/Thromboendarterectomy

Mission

Chronic thromboembolic pulmonary hypertension (CTEPH) is an unusual and progressive disease that causes pulmonary arterial occlusion, gas exchange impairment, right heart failure and eventually death in 3-5 years if left untreated. The disease is sufficiently uncommon and presenting symptoms non-specific that most individual practitioners do not have sufficient patients to develop expertise in its management. The clinical faculty at UAB manage CTEPH by focusing primarily surgical resection, namely pulmonary thromboendarterectomy.

Objectives

The UAB/HSF Pulmonary Thromboendarterectomy Clinic has the following objectives: to provide comprehensive, state of the art clinical and surgical care to patients with pulmonary vascular disease due to chronic thromboembolic pulmonary hypertension (CTEPH), to serve as a regional educational resource for physicians and sub-specialty trainees in pulmonary, cardiology, radiology, pathology, anesthesia and cardiothoracic surgery, to acquire new knowledge through maintenance of a database, clinical trials, and refinement of surgical technique, and to disseminate that knowledge by way of publication and other educational activities.

About Our Practice

Drs. Keith Wille and David McGiffin complete a comprehensive clinical evaluation of all patients and a multidisciplinary team assists with the final decision to proceed with any surgery. Follow up after the operation includes monitoring of hemodynamic recovery and return of exercise capacity. Patients who are not surgical candidates are referred to the Pulmonary Hypertension and Lung Transplant Clinics at UAB to discuss alternative treatment strategies.

Contacting the Program for Pulmonary Embolism/Thromboendarterectomy

For more information, contact Keith Wille, MD via phone at  (205) 934-7941 or via email at kwille@uabmc.Edu.


Study Explores Changes In Cardiovascular Disease Hospitalization Trends During The COVID-19 Pandemic

In a recent study published in Scientific Reports, a group of researchers examined the variations in cardiovascular disease (CVD) hospital diagnoses in the Netherlands during the coronavirus disease 2019 (COVID-19) pandemic compared to the pre-pandemic period.

Changes in incidence of hospitalization for cardiovascular diseases during the COVID-19 pandemic in The Netherlands in 2020 Study: Changes in incidence of hospitalization for cardiovascular diseases during the COVID-19 pandemic in The Netherlands in 2020. Image Credit: fizkes/Shutterstock.Com

The study revealed significant declines in several CVD incidences but a notable increase in pulmonary embolism (PE).

Background

During the COVID-19 pandemic, global and national reports showed an increase in excess mortality, which is the death rate beyond expected norms. In the Netherlands, there were about 30,000 excess deaths between 2020 and 2021, with 341,508 total deaths. Initially, all excess deaths were directly attributed to COVID-19. By late 2021, only 70% of excess deaths were due to the virus.

While the direct effects of COVID-19 include increased rates of venous thromboembolism (VTE) and other cardiovascular issues in hospitalized and non-hospitalized patients, the indirect impact has been profound, causing healthcare delays and lifestyle changes. Hence, it is important to comprehensively analyze the distribution of non-COVID-19-related diseases during the COVID-19 pandemic.

This will help unveil possibly overlooked issues and prepare for the imminent disease burden. Although decreased diagnoses of some non-COVID-19 diseases, like cerebrovascular events, have been reported by some studies, research on the pandemic's influence on cardiovascular diseases in clinical settings remains limited.

About the study

In the present study, data from the entire Dutch population was utilized, which comprised household income, personal details, mortality rates, and hospital diagnosis data, with more information detailed in supplementary sections.

The primary focus was on cardiovascular disease diagnoses made during hospital stays, referencing a list of various cardiovascular conditions identified through the international classification of diseases (tenth revision, ICD-10) codes. Additionally, the research aimed to outline the 2020 hospitalization trends, particularly concerning COVID-19.

For data analysis, weekly diagnosis rates of cardiovascular diseases were established, with the 2015-2019 data modeling expected 2020 rates if the pandemic had not occurred. Poisson regression models factored in demographics like age, sex, income, and immigration background.

Incidence Rate Ratios (IRRs) for 2020 vs. 2019 were determined using Poisson regression and considering patient profiles and medical history. A comorbidity index was developed to adjust for various health conditions. R software facilitated data analysis, leveraging multiple specialized packages. Finally, sensitivity analyses were conducted, focusing on primary hospital diagnoses and excluding imputed diagnoses.

Study results

The present study assessed the personal characteristics of individuals during the initial phase of the COVID-19 pandemic in the Netherlands in 2020 and juxtaposed this data against 2019 figures. In 2020, the study encompassed 17,376,087 people, with an average age of 42.3 years, 50.3% being female. Most participants were of Dutch origin (75.7%), and 9.7% had a comorbidity index of 1 or higher.

From 2015 to 2020, hospital records showed fluctuating VTE incidence rates, including PE and Deep Vein Thrombosis (DVT). There was a notable uptick in VTE rates during the first COVID-19 wave in 2020.

Although these rates initially dipped to pre-pandemic levels, a second surge occurred during the pandemic's second wave. The predominant factor in this surge was a rise in PE hospital diagnoses. Meanwhile, DVT rates in 2020 paralleled those of previous years.

Records from 2020 revealed a decrease in ischemic stroke cases during the pandemic's first wave, which eventually returned to regular levels. A sharp drop in myocardial infarction cases was recorded during the first wave, though these rates rebounded post the initial wave.

The occurrence of transient ischemic attack (TIA) and other arterial thromboembolic events also decreased during the first COVID-19 wave and remained lower throughout the year.

There were recorded weekly incidence rates of atrial fibrillation, heart failure, and other relevant conditions from 2015 to 2020. A drop in incidence was observed for several conditions during the pandemic's first wave when compared to 2019. These rates typically reverted to normalcy by the second wave.

When comparing expected versus actual weekly incidence rates for various cardiovascular diseases in 2020, the patterns largely mirrored those from 2015-2019. Upon narrowing the analysis to primary hospital admissions, VTE's incidence rate during the first wave of the pandemic decreased by 21%. However, during the pandemic's second wave, VTE rates were similar to those in 2019. The incidence rate for PE admissions also dropped by 20% during the first wave. Yet, this rate equaled the 2019 figures during the second wave.

Conversely, the initial analysis suggested a higher VTE rate during 2020, primarily influenced by PE, than in 2019. For DVT as a primary diagnosis, the first wave's incidence rate plunged by 36% compared to 2019. This contrasted the initial analysis, which aligned the DVT rate with 2019 figures. When focusing only on unimputed diagnoses, the findings were consistent across all outcomes.

Conclusions

To summarize, the present study results indicated an uptick in hospital diagnoses for VTE, primarily PE, during both waves of the pandemic in contrast to 2019. Conversely, diagnoses of conditions like ischemic stroke, myocardial infarction, and heart failure saw a decline during the first wave when compared to the prior year.

Potential reasons for these trends could be patients' reluctance to seek care during the pandemic, leading to decreased consultations. Studies indicate that 20% of Dutch participants avoided medical care during the pandemic's first wave, even when experiencing severe symptoms.

Another factor could be physicians' hesitation to refer patients to emergency rooms due to limited resources and infection risks. The elevated VTE incidents, mainly due to PE, during the pandemic have potential long-term implications, as a significant portion of PE survivors could develop post-pulmonary embolism syndrome.


The Diagnosis And Treatment Of Acute Pulmonary Embolism

1. Tapson VF: Acute pulmonary embolism. N Engl J Med 2008; 358: 1037–52. MEDLINE 2. Konstantinides SV: Acute pulmonary embolism revisited: thromboembolic venous disease. Heart 2008; 94: 795–802. MEDLINE 3. Torbicki A, Perrier A, Konstantinides S, et al.: Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276–315. MEDLINE 4. Konstantinides S, Janssens U, Mayer E, Hasenfuß G: Kommentar zu den ESC-Leitlinien „Guidelines on Diagnosis and Management of Acute Pulmonary Embolism". Kardiologe 2009; 3: 272–82. 5. Interdisziplinäre S2-Leitlinie: Lungenembolie (LE). Vasa 2005; 34: 15–24. 6. Walther A, Böttiger BW: Lungenembolie. Wien Med Wochenschr 2008; 158: 610–4. MEDLINE 7. Goldhaber SZ: Pulmonary embolism. Lancet 2004; 363: 1295–305. MEDLINE 8. Walther A, Böttiger BW: Lungenembolie. Notfallmedizin up2date 2007; 2: 57–70. 9. Anderson FA Jr., Spencer FA: Risk factors for venous thromboembolism. Circulation 2003; 107: 9–16. MEDLINE 10. Schulman S: Current strategies in prophylaxis and treatment of venous thromboembolism. Ann Med 2008; 40: 352–9. MEDLINE 11. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386–9. MEDLINE 12. Konstantinides S: Clinical practice. Acute pulmonary embolism.N Engl J Med 2008; 359: 2804–13. MEDLINE 13. Wells PS, Anderson DR, Rodger M, et al.: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416–20. MEDLINE 14. Stein PD, Fowler SE, Goodman LR, et al.: Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354: 2317–27. 15. Van Belle A, Buller HR, Huisman MV, et al.: Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295: 172–9. MEDLINE 16. Perrier A, Roy PM, Sanchez O, et al.: Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med 2005; 352: 1760–8. MEDLINE 17. Sanchez O, Trinquart L, Colombet I, et al.: Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569–77. MEDLINE 18. Becattini C, Vedovati MC, Agnelli G: Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116: 427–33. MEDLINE 19. Grifoni S, Olivotto I, Cecchini P, et al.: Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817–22. MEDLINE 20. Tulevski II, ten Wolde M, van Veldhuisen DJ, et al.: Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol 2007; 116: 161–6. MEDLINE 21. Vuilleumier N, Le Gal G, Verschuren F, et al.: Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 2009; 7: 391–8. MEDLINE 22. Klok FA, Mos IC, Huisman MV: Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425–30. MEDLINE 23. Nolan JP, Deakin CD, Soar J, Böttiger BW, Smith G: European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005; 67(Suppl 1): 39–86. MEDLINE 24. The PREPIC study group: Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112: 416–22. MEDLINE 25. Hoppe H: Optional vena cava filters: indications, management, and results [Optionale Vena-cava-Filter: Indikationen, Management und Ergebnisse]. Dtsch Arztebl Int 2009; 106(24): 395–402. VOLLTEXT e1. Dalen JE: Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis.Chest 2002; 122: 1440–56. MEDLINE e2. Kearon C: Natural history of venous thromboembolism. Circulation 2003; 107: I22–30. MEDLINE e3. Moerchel C, Kroeger K: Prophylaxe tiefer Bein- und Beckenvenenthrombose. Dtsch Arztebl 2007; 104: A 2886–93. VOLLTEXT e4. Dörffler-Melly J, Amann-Vesti B: Diagnostik und Management der akuten Lungenembolie. Herz 2007; 32: 35–41. MEDLINE e5. Dempfle CE: Bestimmung des D-Dimer-Antigens in der klinischen Routine. Dtsch Arztebl 2005; 102(7): A 428–32. VOLLTEXT e6. Dindo D, Breitenstein S, Hahnloser D, et al.: Kinetics of D-dimer after general surgery. Blood Coagul Fibrinolysis 2009; 20: 347–52. MEDLINE e7. Aujesky D, Roy PM, Le Manach CP, et al.: Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 2006; 27: 476–81. MEDLINE e8. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H: Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997: 346–9. MEDLINE e9. Puls M, Dellas C, Lankeit M, et al.: Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224–9. MEDLINE e10. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112: IV1–203. MEDLINE e11. Van de Werf F, Ardissino D, Betriu A, et al.: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66. MEDLINE e12. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133: 454–545. MEDLINE




Comments

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

poliomyelitis treatment

Coronavirus fake news echoes century-old polio fears - Newsroom